An integrated microfluidic chip for immunocapture, preconcentration and separation of β-amyloid peptides

• Published in: Biomicrofluidics 2015-09, Vol.9 (5), p.054117-054117
• Main Authors: Mohamadi, Reza M, Svobodova, Zuzana, Bilkova, Zuzana, Otto, Markus, Taverna, Myriam, Descroix, Stephanie, Viovy, Jean-Louis
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Antibodies; Beads; Biomarkers; Cerebrospinal fluid; Electrokinetics; Electrophoresis; Fluorescence; Hydrogels; Microchannels; Patients; Peptides; Regular; Self-assembly
• ISSN: 1932-1058; 1932-1058
• DOI: 10.1063/1.4931394

We present an integrated microfluidic chip for detection of β-amyloid (Aβ) peptides. Aβ peptides are major biomarkers for the diagnosis of Alzheimer's disease (AD) in its early stages. This microfluidic device consists of three main parts: (1) An immunocapture microcolumn based on self-assembled magnetic beads coated with antibodies specific to Aβ peptides, (2) a nano-porous membrane made of photopolymerized hydrogel for preconcentration, and (3) a microchip electrophoresis (MCE) channel with fluorescent detection. Sub-milliliter sample volume is either mixed off-chip with antibody coated magnetic beads and injected into the device or is injected into an already self-assembled column of magnetic beads in the microchannel. The captured peptides on the beads are then electrokinetically eluted and re-concentrated onto the nano-membrane in a few nano-liters. By integrating the nano-membrane, total assay time was reduced and also off-chip re-concentration or buffer exchange steps were not needed. Finally, the concentrated peptides in the chip are separated by electrophoresis in a polymer-based matrix. The device was applied to the capture and MCE analysis of differently truncated peptides Aβ (1-37, 1-39, 1-40, and 1-42) and was able to detect as low as 25 ng of synthetic Aβ peptides spiked in undiluted cerebrospinal fluid (CSF). The device was also tested with CSF samples from healthy donors. CSF samples were fluorescently labelled and pre-mixed with the magnetic beads and injected into the device. The results indicated that Aβ1-40, an important biomarker for distinguishing patients with frontotemporal lobe dementia from controls and AD patients, was detectable. Although the sensitivity of this device is not yet enough to detect all Aβ subtypes in CSF, this is the first report on an integrated or semi-integrated device for capturing and analyzing of differently truncated Aβ peptides. The method is less demanding and faster than the conventional Western blotting method currently used for research.